Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$0.37+0.03 (+9.66%)
Close on Nov 18, 2026Market cap $68.92MP/E –Yield –
Neumora Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Neumora Therapeutics's free cash flow for the twelve months ending Dec 31, 2023 was -$163.40M. For fiscal 2023 it was -$163.40M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$163.40M | – |
| FY2022 | Dec 31, 2022 | -$115.41M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$51.49M | – |
| Q3 FY2023 | Sep 30, 2023 | -$47.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.39M | – |
See a number that looks wrong?